Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC)
dc.contributor.author | Vogel, A. | |
dc.contributor.author | Chen, L. T. | |
dc.contributor.author | He, A. R. | |
dc.contributor.author | Kim, J. W. | |
dc.contributor.author | Chen, M. H. | |
dc.contributor.author | McNamara, Mairead G | |
dc.contributor.author | Shimizu, S. | |
dc.contributor.author | Gillmore, R. | |
dc.contributor.author | Rey, F. | |
dc.contributor.author | Kim, H. | |
dc.contributor.author | Xiong, J. | |
dc.contributor.author | Makowsky, M. | |
dc.contributor.author | Rokutanda, N. | |
dc.contributor.author | Cohen, G. | |
dc.contributor.author | Oh, D. Y. | |
dc.date.accessioned | 2022-11-30T10:21:25Z | |
dc.date.available | 2022-11-30T10:21:25Z | |
dc.date.issued | 2022 | en |
dc.identifier.citation | Vogel A, Chen LT, He AR, Kim JW, Chen MH, McNamara MG, et al. Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301241. | en |
dc.identifier.doi | 10.1200/JCO.2022.40.16_suppl.4075 | en |
dc.identifier.uri | http://hdl.handle.net/10541/625802 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.4075 | en |
dc.title | Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC) | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Hannover Medical School, Hannover, Germany | en |
dc.identifier.journal | Journal of Clinical Oncology | en |
dc.description.note | en] |